Idiopathic pulmonary fibrosis (IPF) is a progressive and ultimately fatal disease. A major breakthrough in treatment came when, after decades of clinical trials which failed to identify an efficacious treatment regimen, two therapies were successful in Phase-III trials. The advent of these therapies, nintedanib and pirfenidone, meant that for the first time IPF patients had two treatment options that could reduce disease progression. This review summarises the key lessons to be obtained from the clinical trials that led to the current international clinical practice guidelines for the treatment of IPF and provides insights for the design of future clinical trials that are needed if we are to improve outcomes that are clinically meaningful to IPF patients. Clinical trials in IPF have transformed our understanding of how this devastating disease should be treated http://ow.ly/47lM30eX5Pr

中文翻译：

---

特发性肺纤维化：过去 25 年临床试验的经验教训

特发性肺纤维化 (IPF) 是一种进行性和最终致命的疾病。经过数十年的临床试验未能确定有效的治疗方案，两种疗法在 III 期试验中取得成功，治疗取得了重大突破。这些疗法（尼达尼布和吡非尼酮）的出现意味着 IPF 患者第一次有了两种可以减少疾病进展的治疗选择。本综述总结了从导致 IPF 治疗的当前国际临床实践指南的临床试验中获得的关键经验，并为未来临床试验的设计提供了见解，如果我们要改善具有临床意义的结果，就需要这些临床试验。对 IPF 患者。